Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
3000
Hundreds of millions of yenWording
Conditional
How definitive the wording is.This transaction
Bridge loan agreement relating to the acquisition of IntraBio Inc.Disclosing companyShionogi & Co.,Ltd.
Contract Date10 November 2026
Execution Date / Effective Date10 November 2026 (drawdown date)
Target company
Location United States
Consideration and expenses
Funding arrangementsFinanced through a bridge loan from Sumitomo Mitsui Banking Corporation. The loan is scheduled to be refinanced with medium- to long-term funding by the repayment date.
Impact on Business Performance
The impact of this matter on consolidated results for the fiscal year ending March 2027 is minor.
| Item | Details |
|---|---|
| Transaction name | Bridge loan agreement relating to the acquisition of IntraBio Inc. |
| Name of the Subject Company | IntraBio Inc. |
| Location of the Subject Company | United States |
| Funding arrangements | Financed through a bridge loan from Sumitomo Mitsui Banking Corporation. The loan is scheduled to be refinanced with medium- to long-term funding by the repayment date. |
| Impact on Business Performance | The impact of this matter on consolidated results for the fiscal year ending March 2027 is minor. |
| Contract Date | 10 November 2026 |
| Execution Date / Effective Date | 10 November 2026 (drawdown date) |
Items this document does not state (25)
Counterparty nameBusiness Description of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageGoodwill amountAmount of extraordinary income (loss)Date of board resolutionValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To raise the funds required for the acquisition of IntraBio Inc. The borrowed funds are scheduled to be refinanced with medium- to long-term funding by the repayment date.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.